DUBLIN, April 25, 2022 /PRNewswire/ -- The "Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
This pipeline guide provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)
Key Topics Covered:
Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
- Caventure Drug Discovery Inc
- Charleston Laboratories Inc
- Exodos Life Sciences Limited Partnership
- Novartis AG
Drug Profiles
- AX-007 - Drug Profile
- BAM-822 - Drug Profile
- CAV-1001 - Drug Profile
- Drug for Hyperalgesia - Drug Profile
- ketoprofen - Drug Profile
- mol-002291 - Drug Profile
- Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia - Drug Profile
- Small Molecules to Antagonize GPR4 for Arthritis, Hyperalgesia and Oncology - Drug Profile
- ZH-853 - Drug Profile
Dormant Projects
For more information about this report visit https://www.researchandmarkets.com/r/fdqh4b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article